Repair of Bone Erosion in Rheumatoid Arthritis by Denosumab: A High‐Resolution Peripheral Quantitative Computed Tomography Study

Objective To compare the bone healing effects of denosumab and alendronate in female rheumatoid arthritis (RA) patients by high‐resolution peripheral quantitative computed tomography. Methods This is a post hoc analysis of a randomized controlled trial. Forty patients were randomized in a 1:1 ratio...

Full description

Saved in:
Bibliographic Details
Published in:Arthritis care & research (2010) 2017-08, Vol.69 (8), p.1156-1163
Main Authors: Yue, Jiang, Griffith, James F., Xiao, Fan, Shi, Lin, Wang, Defeng, Shen, Jiayun, Wong, Priscilla, Li, Edmund K., Li, Martin, Li, Tena K., Zhu, Tracy Y., Hung, Vivian W., Qin, Ling, Tam, Lai‐Shan
Format: Article
Language:English
Subjects:
Administration, Oral
Aged
Alendronate - administration & dosage
Alendronic acid
Antirheumatic Agents - administration & dosage
Arthritis, Rheumatoid - diagnostic imaging
Arthritis, Rheumatoid - drug therapy
Bisphosphonates
Bone density
Bone Density - drug effects
Bone Density Conservation Agents - administration & dosage
Bone healing
Bone mineral density
Computed tomography
Denosumab - administration & dosage
Female
Follow-Up Studies
Humans
Immunotherapy
Injections, Subcutaneous
Male
Metacarpal
Middle Aged
Monoclonal antibodies
NF-κB protein
Osteosclerosis
Rheumatoid arthritis
Tomography
Tomography, X-Ray Computed - methods
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective To compare the bone healing effects of denosumab and alendronate in female rheumatoid arthritis (RA) patients by high‐resolution peripheral quantitative computed tomography. Methods This is a post hoc analysis of a randomized controlled trial. Forty patients were randomized in a 1:1 ratio to receive either subcutaneous denosumab (60 mg) once or oral alendronate (70 mg) weekly for 6 months. The size of individual bone erosions and the presence and extent of erosion‐associated sclerosis (marginal osteosclerosis) were measured in the second metacarpal head of the nondominant hand at baseline, 3 months, and 6 months. Results Forty‐two erosions were identified at baseline. After 6 months, the width, depth, and volume of erosion significantly decreased in the denosumab group (−0.23 mm, −0.16 mm, −0.91 mm3, respectively; all P 
ISSN:2151-464X
2151-4658
DOI:10.1002/acr.23133